Progyny Earnings Call Transcripts
Fiscal Year 2026
-
Administrative adjustments led to a reduction in eligible lives, but utilization rates remain strong and stable. The new fully insured product targets small employers, with risk managed through data-driven underwriting and annual premium adjustments. AI and data investments are enhancing patient and provider experiences.
-
Strong client retention, stable utilization, and expanded offerings position the business for continued growth. New products target unmet needs in the fully insured market, with positive early feedback and no financial impact expected until 2027. Margin expansion is anticipated post-2026 as investments taper.
-
Utilization and consumption remained stable in 2025, with growth driven by new members and consistent treatment patterns. Strategic investments in IT, product expansion into menopause and benefit navigation, and the launch of Progyny Select are positioning the business for broader reach. Risk controls, AI-driven efficiencies, and a strong financial position support ongoing growth.
-
Client retention remains near 100% with 900,000 new lives added, and new services and global expansion are underway. Progyny Select targets small employers, expanding the addressable market by 50 million lives, with financial impact expected from 2027. Medical cost trends remain well below industry averages.
Fiscal Year 2025
-
Record 2025 results with double-digit revenue and adjusted EBITDA growth, strong cash flow, and near 100% client retention. 2026 guidance projects continued growth, margin expansion, and lower stock-based compensation, with new products targeting smaller employers and a diversified client base.
-
The company leads the U.S. fertility benefits market, with stable utilization and high client retention. Growth is driven by new product launches, expansion into smaller employer markets, and supportive regulatory changes. Recent financial performance and capital strength support continued expansion.
-
Third quarter revenue and profitability exceeded guidance, prompting a full-year outlook raise. Strong client retention, new product launches, and a $200M share repurchase program highlight continued momentum and market leadership.
-
Q2 2025 saw record revenue and adjusted EBITDA, with strong growth in core business and gross margin expansion. Full-year guidance was raised, supported by robust client demand, new product launches, and strategic partnerships, while financial flexibility was enhanced with a new credit facility.
-
Record revenue and profitability were achieved in 2024, with strong client growth and new product launches. All director nominees and auditors were approved, but executive compensation was not. Strategic focus includes digital integration and expanded partnerships.
-
Utilization and care consumption trends have stabilized after recent volatility, with guidance for 2025 reflecting this. New products are gaining traction, and market expansion efforts target both fully insured and global populations. Investments in digital integration and infrastructure aim to enhance member experience and retention.
-
Double-digit revenue and adjusted EBITDA growth set new records, with gross margin expansion and strong cash flow. Full-year guidance was raised, driven by robust client growth, new product launches, and continued high member engagement, despite macroeconomic uncertainties.
-
ART cycle utilization rebounded after a Q3 dip, with Q4 and Q1 showing normalized patterns and strong financial results. Client growth was robust, retention remained high, and expanded offerings drove upsell success. Investments focus on integration, global expansion, and digital experience.
-
Q4 saw a strong rebound in ART cycle utilization, with new client cohorts performing as expected. Data-driven forecasting and product innovation, including expanded menopause and maternity services, support continued growth. Investments focus on global reach and digital integration.
-
A leading women's health benefits provider highlighted strong market growth, high client retention, and expansion into new services like menopause and postpartum. Differentiated by data-driven outcomes, flexible plan design, and strategic partnerships, the company remains profitable and well-positioned for continued TAM expansion.
Fiscal Year 2024
-
Q4 and full-year results exceeded guidance, driven by strong client growth, high retention, and new service adoption. 2025 guidance reflects the impact of a large client transition and continued investment in digital and product expansion, with revenue growth projected at 1–5%.
-
Utilization rates remain high, though cycles per utilizer dipped in 2023, with early signs of recovery. Sales momentum is strong, client retention is 99%, and new product adoption is growing. Long-term growth prospects remain robust despite short-term variability.
-
Q3 revenue grew 2% year-over-year, but results missed guidance due to lower ART cycle consumption despite stable utilization rates. Strong client growth, high retention, and new women's health offerings support a positive long-term outlook, though guidance remains cautious due to ongoing variability.
-
The company outlined a strategy to double revenue and expand Adjusted EBITDA 2.5x by 2028, driven by new women's health products, deeper client penetration, and global expansion. New offerings in menopause and maternity are expected to contribute 8%-10% of revenue, with a focus on high retention, margin expansion, and a differentiated member experience.
-
Revenue grew 9% year-over-year to $304.1M, but full-year guidance was lowered by 5% due to lower ART cycles per utilizer and a net reduction in covered lives. Despite this, early selling season results are strong, margins expanded, and new partnerships and global acquisitions support long-term growth.
-
Q1 utilization was impacted by the Alabama ruling but improved in April, supporting Q2 guidance. Membership growth remains strong with 200,000 new lives going live in the back half, and selling season metrics are favorable. No regulatory threats are seen, and new ancillary products are in development.